Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 17/20 | 0.84 |
| ▸ | WDR77 | Q9BQA1 | 16/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24625951 | 0.93 | PRMT5 (0.84) | PRMT5WDR77 | |
| SCHEMBL18039043 | 0.92 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL18009839 | 0.92 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL21413928 | 0.92 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL24626470 | 0.89 | PRMT5 (0.72) | PRMT5WDR77 | |
| SCHEMBL24625909 | 0.86 | PRMT5 (0.77) | PRMT5WDR77 | |
| SCHEMBL21413929 | 0.85 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL21391701 | 0.85 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL18026294 | 0.85 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL30382155 | 0.85 | PRMT5 (1.00) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218732-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2022-07-14 | — | — | US | disclosed |
| US-20220168329-A1 | COMBINATORIAL DRUG TREATMENT OF CANCER | UNIVERSITY OF VIRGINIA | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168329-A1 | COMBINATORIAL DRUG TREATMENT OF CANCER | DDIT3, PRMT3, PRMT1 | PRMT5 7/4885WDR77 146/4885 |
| US-20220218732-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRMT5, PRMT6, PRMT1 | PRMT5 1/4885WDR77 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.